Table 3.
Rates of resistance and dosing of oral agents for treatment of CA-MRSA infections.
| Antimicrobial agent | Resistance rates | Typical adult oral dosing | Comments |
|---|---|---|---|
| Clindamycin | 3–24% | 300 TID | D-test should be performed. Excellent activity against strep. Increasing resistance a concern. |
| Doxycycline Minocycline |
19–24% | 100 mg BID 100 mg BID |
Doxycycline and minocycline probably active against tetracycline resistant strains. |
| Trimethoprim-sulfamethoxazole | 0–10% | 1–2 DS (160/800 mg) BID | Low resistance rates in community, reasonable option for empiric therapy. |
| Rifampin | <1% | 600 mg QD | Should not be used alone; potential for significant drug interactions |
| Fusidic acid | <5% | 500 mg TID | Should not be used alone; limited experience in children |
| Linezolid | < 1 % | 600 mg PO BID | Expensive. |
1
Rates shown are for tetracycline and are likely to be < 5% or less for doxycycline and minocycline